News
Important Only
Russia's Lavrov, U.S.' Rubio conclude meeting in Malaysia, TASS reports
MOSCOW, July 10 (Reuters) - A meeting between Russian Foreign Minister Sergei Lavrov and U.S. Secretary of State Marco Rubio has concluded, Russia's TASS state news agency reported on Thursday.The event took place on the sidelines of a regional meeting of Association of Southeast Asian Nations f...Reuters
Thu, Jul 10
Polestar's quarterly EV sales jump as offers attract more buyers
July 10 (Reuters) - Polestar PSNY.O reported a surge in second-quarter sales on Thursday, as offers and discounts helped boost sales in its home market of Europe amid a challenging macroeconomic environment.The Sweden-based company sold an estimated 18,049 vehicles in the second quarter, it said, a ...Reuters
Thu, Jul 10
Allianz Commercial names Stait and Baker to lead UK markets
By Navneeta NandanJuly 10 - (The Insurer) - Allianz Commercial announced on Thursday that Graham Stait and Luke Baker have been appointed as director of UK markets and director of UK global, respectively.Stait most recently served as director of mid-market on interim basis. His new role of director ...Reuters
Thu, Jul 10
Helen of Troy misses Q1 profit and revenue estimates
OverviewHelen of Troy fiscal Q1 sales decline 10.8%, missing analyst expectations, per LSEG dataBeauty products and home tools maker's adjusted EPS for fiscal Q1 misses consensusCo faces substantial operating loss due to non-cash asset impairment chargesOutlookCompany expects Q2 fiscal 2026 net ...Reuters
Thu, Jul 10
U.S. FDA Accepts New Drug Application For Merck’S Doravirine/Islatravir
July 10 (Reuters) - Merck & Co Inc MRK.N:U.S. FDA ACCEPTS NEW DRUG APPLICATION FOR MERCK’S DORAVIRINE/ISLATRAVIR, AN INVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG REGIMEN FOR TREATMENT OF ADULTS WITH VIROLOGICALLY SUPPRESSED HIV-1 INFECTIONMERCK & CO INC - FDA SETS TARGET ACTION DATE OF APRIL ...Reuters
Thu, Jul 10
Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence
July 10 (Reuters) - Pfizer Inc PFE.N:XTANDI® PLUS LEUPROLIDE SIGNIFICANTLY IMPROVES SURVIVAL OUTCOMES IN MEN WITH NON-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH HIGH-RISK BIOCHEMICAL RECURRENCEPFIZER: EMBARK MET KEY SECONDARY ENDPOINTPFIZER INC - XTANDI PLUS LEUPROLIDE IMPROVES OVERALL SURVIV...Reuters
Thu, Jul 10
German exporters don't want US trade deal 'at any price', says trade group
By Rene Wagner and Maria Martinez BERLIN, July 10 (Reuters) - German exporters do not want a deal at any price in the trade conflict with the United States, said Dirk Jandura, head of the BGA trade lobby."Our interests must be reflected in an agreement with the U.S.," Jandura said on Thur...Reuters
Thu, Jul 10
Rhythm Pharmaceuticals Announces Pricing Of Upsized Public Offering Of Common Stock
July 10 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:RHYTHM PHARMACEUTICALS, INC. ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCKRHYTHM PHARMACEUTICALS INC - PRICES UPSIZED PUBLIC OFFERING AT $85 PER SHARERHYTHM PHARMACEUTICALS INC - GROSS PROCEEDS FROM OFFERING EXPECTED TO BE $175 MIL...Reuters
Thu, Jul 10
Yunhong Green CTI Ltd Enters Consulting Agreement With Third-Party Firm
July 10 (Reuters) - Yunhong Green CTI Ltd YHGJ.O:YUNHONG GREEN CTI LTD - ON JULY 4 ENTERS CONSULTING AGREEMENT WITH THIRD-PARTY FIRM- SEC FILINGYUNHONG GREEN CTI LTD - AGREEMENT TO ASSESS STRATEGIC ALTERNATIVES FOR CO - SEC FILINGReuters
Thu, Jul 10
Partial court victory for Michelin in fight against EU cartel dawn raids
EU court annuls part of EU decision authorising raidsEU has no sufficiently serious indications for earlier periodRegulators cannot use as evidence some information seizedCourt decision could impact size of potential finesBy Foo Yun Chee BRUSSELS, July 9 (Reuters) - French tyre maker Michelin MIC...Reuters
Thu, Jul 10
Soleno Therapeutics Announces Proposed $200 Million Public Offering Of Common Stock
July 10 (Reuters) - Soleno Therapeutics Inc SLNO.O:SOLENO THERAPEUTICS ANNOUNCES PROPOSED $200 MILLION PUBLIC OFFERING OF COMMON STOCKSOLENO THERAPEUTICS INC - PROCEEDS TO FUND VYKAT XR COMMERCIALIZATION FOR PRADER-WILLI SYNDROMESOLENO THERAPEUTICS INC - GRANTS UNDERWRITERS OPTION FOR $30 MILLION AD...Reuters
Thu, Jul 10
Soleno Therapeutics Announces Preliminary Financial And Operational Results for Q2
July 10 (Reuters) - Soleno Therapeutics Inc SLNO.O:SOLENO THERAPEUTICS ANNOUNCES PRELIMINARY FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025SOLENO THERAPEUTICS: EXPECTS NET REVENUE FROM SALES OF VYKAT(TM) XR, FOR THREE MONTHS ENDED JUNE TO BE BETWEEN $31.0 MILLION - $33....Reuters
Thu, Jul 10
